ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • innate immunity and rheumatoid arthritis
  • innate immunity and rheumatoid arthritis (RA)
  • innate immunity and scleroderma
  • innate immunity and spondylarthritis
  • innate immunity and spondylarthropathy
  • innate immunity and systemic lupus erythematosus (SLE)
  • innate immunity and systemic sclerosis
  • innate immunity and therapy
  • innate immunity and toll-like receptors
  • innate immunity and vaccines
  • innate immunity and vasculitis
  • Innate Immunity Rheumatic Disease
  • Insufficiency Fracture
  • insulin resistance
  • insulin resistance and lipids
  • insulin resistance and osteoarthritis
  • insulin resistance and platelets
  • insulin resistance and psoriasis
  • insulin resistance and psoriatic arthritis
  • insulin resistance and resting energy expenditure
  • insulin resistance and rheumatoid arthritis (RA)
  • insulin resistance and systemic lupus erythematosus (SLE)
  • insulin resistance and uric acid
  • Insulin-like growth factor
  • Insulin-like Growth Factor (IGF)
  • insulin-like growth factor and microbiome
  • insulin-like growth factor and osteoarthritis
  • insulin-like growth factor and rheumatoid arthritis (RA)
  • insulin-like growth factor and scleroderma
  • Insurance
  • insurance and mental health
  • Insurance and prescribing trends
  • insurance and rheumatoid arthritis
  • insurance and rheumatoid arthritis (RA)
  • Insurance and systemic lupus erythematosus (SLE)
  • integrated safety
  • Integrated Summary of Safety
  • Integrative
  • integrative and systemic lupus erythematosus (SLE)
  • Integrins
  • integrins and neutrophils
  • integrins and osteoarthritis
  • integrins and osteoclastogenesis
  • Integrins and osteoclasts
  • integrins and rheumatoid arthritis (RA)
  • integrins and scleroderma
  • integrins and synovial cells
  • integrins and uveitis
  • Intensive care
  • intensive care and vasculitis
  • interdisciplinary rheumatology team
  • interdisciplinary rheumatology team and medical education
  • interdisciplinary rheumatology team and methotrexate (MTX)
  • interdisciplinary rheumatology team and pediatrics
  • Interdisciplinary rheumatology team and spondylarthritis
  • interdisplinary
  • interdisplinary and medical education
  • interdisplinary and pediatric rheumatology
  • interferon
  • Interferon activity
  • interferon and B cell tolerance
  • interferon and outcome measures
  • Interferon induced genes and Type 1 Interferon
  • Interferon regulated genes
  • interferons
  • interferons and apoptosis
  • interferons and bioinformatics
  • interferons and Gene Expression
  • interferons and genetics
  • interferons and ibm
  • interferons and interleukins (IL)
  • interferons and interstitial lung disease
  • interferons and intima medial thickness
  • interferons and Janus kinase (JAK)
  • interferons and juvenile dermatomyositis
  • interferons and leukocytes
  • interferons and lupus nephritis
  • interferons and macrophage activation syndrome
  • interferons and macrophages
  • interferons and metabolomics
  • interferons and monoclonal antibodies
  • interferons and monocytes
  • Interferons and morphea
  • interferons and mouse model
  • interferons and muscle biopsy
  • interferons and myositis
  • interferons and neonatal disorders
  • interferons and nephritis
  • interferons and nervous system lupus
  • interferons and neutrophils
  • interferons and novel
  • interferons and osteoblasts
  • Interferons and osteopontin
  • interferons and pathogenesis
  • interferons and pediatric rheumatology
  • interferons and pediatrics
  • interferons and polymorphism
  • interferons and prognostic factors
  • interferons and prolactin
  • interferons and proteomics
  • Interferons and rheumatoid arthritis
  • interferons and rheumatoid arthritis (RA)
  • interferons and salivary gland
  • interferons and serologic tests
  • interferons and signal transduction
  • interferons and Sjogren's syndrome
  • Interferons and skin
  • interferons and synovial cells
  • Interferons and systemic lupus erythematosus (SLE)
  • interferons and systemic sclerosis
  • interferons and therapeutic targeting
  • interferons and thrombosis
  • interferons and tofacitinib
  • interferons and tolerance
  • interferons and toll-like receptors
  • interferons and transcription factor
  • interferons and treatment
  • interferons and treatment options
  • interferons and tumor necrosis factor (TNF)
  • interferons and uveitis
  • interferons and vaccines
  • interferons and vasculitis
  • interferons and viruses
  • Interlekin-22
  • interleukin 6 and adenosine
  • Interleukin-18 (IL-18)
  • Interleukin-23
  • interleukin-6 inhibitors
  • interleukin6
  • Interleukins
  • interleukins (IL)
  • interleukins (IL) and anti-TNF therapy
  • interleukins (IL) and citrullination
  • Interleukins (IL) and juvenile idiopathic arthritis (JIA)
  • interleukins (IL) and kinase
  • Interleukins (IL) and lupus nephritis
  • interleukins (IL) and macrophage activation syndrome
  • interleukins (IL) and macrophages
  • interleukins (IL) and matrix metalloproteinase (MMP)
  • interleukins (IL) and meta-analysis
  • interleukins (IL) and metabolic syndrome
  • interleukins (IL) and microbiome
  • interleukins (IL) and monoclonal antibodies
  • interleukins (IL) and mouse model
  • interleukins (IL) and natural killer (NK) cells
  • interleukins (IL) and osteoarthritis
  • interleukins (IL) and osteoblasts
  • Interleukins (IL) and osteoclasts
  • interleukins (IL) and osteoporosis
  • interleukins (IL) and pain
  • interleukins (IL) and pain management
  • interleukins (IL) and pathogenesis
  • interleukins (IL) and patient-reported outcome measures
  • Interleukins (IL) and psoriatic arthritis
  • Interleukins (IL) and quality of life
  • interleukins (IL) and radiography
  • interleukins (IL) and randomized trials
  • interleukins (IL) and registry
  • interleukins (IL) and regulatory cells
  • interleukins (IL) and remission
  • interleukins (IL) and rheumatoid arthritis
  • interleukins (IL) and rheumatoid arthritis (RA)
  • interleukins (IL) and rituximab
  • interleukins (IL) and safety
  • interleukins (IL) and salivary gland
  • Interleukins (IL) and signal transduction
  • interleukins (IL) and spondylarthritis
  • interleukins (IL) and spondylarthropathy
  • interleukins (IL) and systemic lupus erythematosus (SLE)
  • interleukins (IL) and systemic sclerosis
  • interleukins (IL) and takayasu arteritis
  • Interleukins (IL) and tendonitis/bursitis
  • interleukins (IL) and therapeutic targeting
  • interleukins (IL) and therapy
  • interleukins (IL) and tocilizumab
  • interleukins (IL) and treatment
  • interleukins (IL) and tumor necrosis factor (TNF)
  • interleukins (IL) and vasculitis
  • interleukins-10
  • internal anal sphicter
  • international
  • international and juvenile dermatomyositis
  • international and rheumatoid arthritis (RA)
  • international and social media
  • International Classification of Functioning
  • internet
  • internet and rheumatoid arthritis (RA)
  • interstitial lung disease
  • interstitial lung disease and administrative databases
  • interstitial lung disease and anti-MDA5 antibody
  • interstitial lung disease and autoantibodies
  • interstitial lung disease and endoscopy
  • interstitial lung disease and health care cost
  • interstitial lung disease and Idiopathic Inflammatory Myopathies (IIM)
  • Interstitial lung disease and juvenile dermatomyositis
  • interstitial lung disease and KL-6
  • interstitial lung disease and Lung Disease
  • interstitial lung disease and Medicare
  • interstitial lung disease and meta-analysis
  • Interstitial lung disease and mixed connective tissue disease (MCTD)
  • First |
  • « Previous Page
  • 27
  • 28
  • 29
  • 30
  • 31
  • [32]
  • 33
  • 34
  • 35
  • 36
  • 37
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology